Deutschland Times
SEE OTHER BRANDS

The latest news from Germany

Welcome to Deutschland Times

Deutschland Times

Press Releases

Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration GAL-101 effectively crosses the blood-brain barrier, supporting further development in Alzheimer’s disease A Phase 2 trial in Alzheimer’s...

Show All
Deutschland Times

Latest News

Show All

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions